> News > ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
09.12
2019

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting

Lausanne, Switzerland, December 9, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced interim efficacy and safety data on 52 patients in the ongoing pivotal 145-patient Phase 2 clinical trial of ADCT-402 (loncastuximab tesirine), demonstrating its potential as a single agent for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Carmelo Carlo-Stella, MD, Section Chief, Lymphoid Malignancies and Cancer Therapeutics, Humanitas Cancer Center, Humanitas University, and an investigator for the trial, presented the data today during an oral session at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

Read full article